<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01364376</url>
  </required_header>
  <id_info>
    <org_study_id>ZYYY-GC1105</org_study_id>
    <nct_id>NCT01364376</nct_id>
  </id_info>
  <brief_title>S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma</brief_title>
  <acronym>Focus</acronym>
  <official_title>S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma: a Multi-center, Open-labeled, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <brief_summary>
    <textblock>
      This is a randomized multicenter controlled study of oxaliplatin, leucovorin calcium , plus
      5-fluorouracil (FOLFOX) compared with S-1 plus oxaliplatin (SOX) as perioperative
      chemotherapy for advanced gastric cancer.

      Hypothesis: SOX is not inferior to FOLFOX as perioperative chemotherapy for advanced gastric
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival(PFS)</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical response</measure>
    <time_frame>6 or 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological response</measure>
    <time_frame>within 10 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with grade 3/4 adverse Events</measure>
    <time_frame>6 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">583</enrollment>
  <condition>Stomach Neoplasms</condition>
  <arm_group>
    <arm_group_label>FOLFOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium</intervention_name>
    <description>FOLFOX:
oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles
SOX:
oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy</description>
    <arm_group_label>FOLFOX</arm_group_label>
    <arm_group_label>SOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed gastric adenocarcinoma,diagnosed as locally advanced gastric
             cancer and primary tumor invades or penetrates serosa

          -  Ambulatory males or females, aged 18-80 years old

          -  ECOG score 0-2

          -  Given informed consent

          -  Life expectancy more than 3 months

          -  Measurable lesion

          -  Normal cardiac, hepatic, renal, and bone marrow
             function(WBC:3.5×10^9/l~12×10^9/l;PLT:&gt;100×109/l;Bil:&lt;1.5 fold of upper limit value;
             ALT/AST:&lt;2.5 fold of upper limit value;Ccr:&gt;80ml/min;Cr:1.5mg/dl)

        Exclusion Criteria:

          -  Prior stomach surgery

          -  Previous cytotoxic chemotherapy, radiotherapy, target therapy or immunotherapy for any
             tumor

          -  History of another malignancy except cured basal cell carcinoma of skin and cured
             carcinoma in-situ of uterine cervix

          -  distant metastasis(such as No.16 and No.13 lymphnode,liver, lung,brain,bones or
             peritoneal metastasis)

          -  Severe bleeding

          -  Bowel obstruction, ileus or complete pyloric obstruction

          -  Serious uncontrolled concomitant disease

          -  History of myocardial infarction in 6 months

          -  Woman with on-going pregnancy or breast-feeding, or contemplating pregnancy

          -  Systemic treatment with corticosteroid

          -  Patients judged inappropriate for the trial by the physicians
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiren Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Medical School of Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Medical School of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Medical School of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiaxing First Hospital</name>
      <address>
        <city>Jiaxing</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ningbo Medical Treatment Center Lihuili Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of Wenzhou medical college</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2011</study_first_posted>
  <last_update_submitted>August 20, 2016</last_update_submitted>
  <last_update_submitted_qc>August 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Jiren Yu</investigator_full_name>
    <investigator_title>Chief doctor</investigator_title>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

